Abbott Libre Duo 10 Day and Libre Duo
Last checked September 28, 2026
This site gives general information, not medical advice. Talk to your doctor or diabetes team before changing how you monitor or treat any condition.
| Type | Continuous ketone sensor |
|---|---|
| Maker | Abbott |
| Measures | Glucose and ketones in the fluid under the skin, from one sensor |
| Wear or use | Libre Duo 10 Day: up to 10 days (age 2+). Libre Duo: up to 15 days (adults, Europe only) |
| Readings | Measured every minute; glucose shown on the phone, ketones tracked in the background with an Urgent High Ketones alarm above 3.0 mmol/L |
| App | Libre app; LibreView (clinics) and LibreLinkUp (caregivers) |
| US status | FDA De Novo authorization, 25 Aug 2026 (Libre Duo 10 Day, people with diabetes aged 2+). Prescription only |
| UK status | No UK launch announced as of 28 Sep 2026 |
| EU status | CE mark, 27 May 2026 (Libre Duo and Libre Duo 10 Day) |
| Price | Not announced yet |
| Availability | Not on sale yet: US launch planned for later in 2026; first European countries later in 2026 |
| Where to buy | Abbott: Libre Duo 10 Day page |
What it is
Libre Duo is Abbott’s first sensor that measures both glucose and ketones from one filament under the skin. The FDA authorized the Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System on 25 August 2026 through its De Novo pathway, the route for new kinds of device. The FDA describes it as the first wearable device that continuously monitors both ketone levels and blood sugar (FDA, Abbott).
In Europe, Abbott received a CE mark on 27 May 2026 for two versions: Libre Duo, worn for up to 15 days by adults 18 and over, and Libre Duo 10 Day, worn for up to 10 days by people aged 2 and over (Abbott).
Who it is for
People with type 1 or type 2 diabetes aged 2 and over who take insulin or other glucose-lowering medicines, including SGLT2 inhibitors, and who are at higher risk of raised ketones (Abbott). In the US it is prescription only (Abbott US).
For people with type 1 diabetes, and others at risk of diabetic ketoacidosis (DKA), ketone levels are a medical matter. Follow the plan from your diabetes team and the guidance from the NHS or the American Diabetes Association. No consumer ketone sensor replaces the testing your care team asks for.
How it shows ketones
Glucose shows on the phone minute by minute, as on other Libre sensors. Ketones are tracked in the background, and an Urgent High Ketones alarm sounds when ketones go above 3.0 mmol/L. There is also an Urgent Low Glucose alarm below 55 mg/dL (Abbott). That 3.0 mmol/L level matches the “urgent high” alarm threshold in the international expert recommendations on continuous ketone monitoring (summary). The FDA notes that ketone results should always be read alongside glucose readings and symptoms (FDA).
The evidence behind it
The FDA reviewed six clinical studies with more than 600 participants aged 2 and over. The FDA says the device tracked clinically meaningful differences in ketone levels and picked up raised ketones before DKA set in (FDA). In Abbott’s studies, 84.1% of sensors worn by adults and 68.8% worn by children lasted the full 10 days (Abbott). See how accurate ketone sensors are for the published data.
Limitations
- Not on sale anywhere yet (as of 28 September 2026).
- The price has not been announced. Abbott says it will work with insurers and payers (MedTech Dive).
- Not every sensor lasts the full wear time (figures above).
- The expert panel behind the recommendations advises keeping a backup blood ketone meter to check readings against symptoms (summary).
When and where
- US: launch planned for later in 2026, through the Libre app. Abbott expects it to work with Beta Bionics’ iLet and Sequel’s twiist insulin systems by the end of 2026, and Insulet, Tandem and MiniMed systems in 2027 (Abbott).
- Europe: launch in selected European countries later in 2026 (Abbott).
- UK: no UK launch date announced. See buying in the UK vs the US.